2 Circulating CD4+ T cells in people with HIV and history of pulmonary tuberculosis have more
 3 intact HIV DNA

4

- 5 Marc Antoine Jean Juste^{1*}, Yvetot Joseph^{1*}, Dominique Lespinasse¹, Alexandra Apollon¹,
- 6 Parmida Jamshidi², Myung Hee Lee², Maureen Ward², Esther Brill², Yanique Duffus², Uche
- 7 Chukwukere², Ali Danesh², Winiffer Conce Alberto², Daniel W. Fitzgerald², Jean W. Pape^{1,2}, R.
- 8 Brad Jones², Kathryn Dupnik²
- 9
- 10 ¹ GHESKIO Centers, Port au Prince, Haiti
- ² Department of Medicine, Weill Cornell Medicine, New York, NY 10021
- 12
- 13 * There are two co-first authors. Dr. Jean Juste is listed first because the pilot cohort for which
- 14 he supervised enrollment contributed a larger number of participants to this study.

15

- 16
- 17 <u>Corresponding author</u>:
- 18 Kathryn M. Dupnik
- 19 Weill Cornell Medicine Center for Global Health
- 20 402 E 67th Street, 2nd floor
- 21 New York NY 10065
- 22 Phone: 646-962-8140
- 23 Email: kad9040@med.cornell.edu

- 25 <u>Conflict of interest statement</u>:
- 26 The authors have declared that no conflict of interest exists.

27 ABSTRACT

28

Background: The primary barrier to curing HIV infection is the pool of intact HIV proviruses integrated into host cell DNA throughout the bodies of people living with HIV (PLHIV), called the HIV reservoir. Reservoir size is impacted by the duration of HIV infection, delay in starting antiretroviral therapy (ART), and breakthrough viremia during ART. The leading infectious cause of death worldwide for PLHIV is TB, but we don't know how TB impacts the HIV reservoir.

<u>Methods:</u> We designed a case-control study to compare HIV provirus-containing CD4 in PLHIV with vs. without a history of active TB disease. Study participants in the pilot and confirmatory cohort were enrolled at GHESKIO Centers in Port au Prince, Haiti. Intact and non-intact proviral DNA were quantified using droplet digital PCR of PBMC-derived CD4 cells. For a subset, Th1 and Th2 cytokines were assayed in plasma. Kruskal-Wallis tests were used to compare medians with tobit regression for censoring.

40 <u>Results</u>: In the pilot cohort, we found that PLHIV with history of active pulmonary TB (n=20) had 41 higher intact provirus than PLHIV without history of active TB (n=47) (794 vs 117 copies per million 42 CD4, respectively; p<0.0001). In the confirmatory cohort, the quantity of intact provirus was higher 43 in the TB group (n=13) compared with the non-TB group (n=18) (median 102 vs. 0 intact provirus 44 per million CD4, respectively p=0.03). Additionally, we found that the frequencies of CD4+ T cells 45 with any detectable proviral fragment was directly proportional to the levels of IL1B (p= 0.0025) 46 and IL2 (p=0.0002).

47 <u>Conclusions</u>. This is the first assessment of HIV provirus using IPDA in a clinical cohort from a 48 resource limited setting, and the finding of larger reservoir in PLHIV with history of TB has 49 significant implications for our understanding of TB-HIV coinfection and HIV cure efforts in TB-50 endemic settings.

52 MANUSCRIPT

53

54 The primary barrier to curing HIV infection is the pool of intact HIV proviruses integrated into host 55 cell DNA throughout the bodies of people living with HIV (PLHIV), called the HIV reservoir. 56 Reservoir size is impacted by the duration of HIV infection, delay in starting antiretroviral therapy 57 (ART), and breakthrough viremia during ART. Increased reservoir size has been associated with 58 worse clinical outcomes, including neurocognitive impairment (1). The leading infectious cause of 59 death worldwide for PLHIV is TB, but we don't know how TB impacts the HIV reservoir. An 60 approximation of reservoir size can be attained by quantitative PCR of HIV DNA in peripheral 61 blood mononuclear cells (PBMC). One group used this approach to study HIV DNA levels in 62 PBMCs from PLHIV with and without active pulmonary TB in Uganda and did not see a statistically 63 significant difference (2). However, in a cohort in China, PLHIV with history of TB had a higher 64 level of circulating HIV DNA than people without TB, but they also had higher viral load pre-ART 65 (3). People with TB-HIV coinfection may have increased risk of virological failure and 66 breakthrough viremias, resulting from or contributing to greater quantities of HIV DNA in 67 circulating CD4+ T cells.

68

The emerging gold standard for the measurement of HIV reservoirs is the intact proviral DNA asay (IPDA), which distinguishes intact from defective proviruses, the latter being much more numerous (4). We applied a modified IPDA (5) to a cohort of people with HIV in a resource-limited setting with a TB syndemic to determine how quantities of CD4+ T cells containing HIV provirus vary in people who had had active bacteriologically confirmed pulmonary TB disease concurrent with or after diagnosis of HIV.

75

Using IPDA (*see supplemental methods*), we measured proviral loads for 100 PLHIV participating
in a TB study at GHESKIO Centers in Port au Prince, Haiti, 50 people with active or history of

78 bacteriologically confirmed pulmonary TB and 50 people with no history of TB (Supplemental 79 Table 1). Within the total cohort, there was a nearly 8-fold difference in intact provirus levels 80 between current or history of TB vs. no TB (median 881 vs 116 copies per million CD4+ T cells, 81 respectively; p=0.0001) (Figure 1A). Tobit regression of detectable intact provirus also showed 82 statistically significant difference in intact provirus (p < 0.0001) between the TB and non-TB 83 groups. There was no statistically significant difference in intact provirus between people with 84 newly diagnosed untreated TB (n=25) vs. history of TB or TB currently being treated (n=25) 85 (median 897 vs. 865 copies per million CD4+ T cells, respectively; p=0.92; Supplemental Figure 86 1A). In the people with no history of TB, the amount of intact provirus in CD4+ T cells was not 87 statistically significantly different by IGRA status (median 80 for IGRA-positive vs.118 for IGRA-88 negative per million CD4, p=0.65; Supplemental Figure 1B).

89

90 To remove potential confounders of the difference in intact provirus observed in the initial groups. 91 we excluded 26 people with HIV diagnosed less than one year before sample collection. We 92 excluded 3 people with no plasma available for p24 testing and 3 people with detectable plasma p24. One person who had TB prior to HIV diagnosis was also excluded. After these adjustments, 93 94 the difference in intact proviral load between TB and no-TB groups remained statistically 95 significant (median 794 vs 117 copies per million CD4, respectively; p=0.0001) by Kruskal-Wallis 96 test as well as by tobit regression (p<0.0001). This difference remained statistically significant 97 when analyzing women and men independently (p< 0.005).

98

99 For the confirmatory study, we began with 34 participants from a study of TB recurrence. One 100 participant's PBMC did not have enough live cells after thawing to have CD4+ T cells selected 101 and DNA extracted so was excluded from downstream analyses. One DNA sample failed QC with 102 no detectable intact, *env* fragment, or *psi* fragment with all tested primer sets and so was 103 excluded. One person had HIV viral load > 1,000 copies/mL as well as detectable p24 after

104 dissociation. This person was excluded as the high-level viremia could have rendered the IPDA 105 quantitation inaccurate. In the final analysis group from the confirmatory cohort (Supplemental 106 Table 2), the quantity of intact provirus was higher in the TB group compared with the non-TB 107 group (median 102 vs. 0 intact provirus per million CD4, respectively p=0.03) (Figure 1B). We 108 also analyzed the intact provirus levels using a tobit regression model with 12 left-censored 109 observations for intact proviral loads less than the lower limit of detection and the difference 110 remained statistically significant (p=0.04). In the participants with no history of TB, there wasn't a 111 statistically significant difference in intact proviral load with IGRA positivity (median 0 vs 9 intact 112 provirus per million CD4, p=0.96; Supplemental Figure 2A). In participants with history of one or 113 recurrent episodes of TB, there was no statistically significant difference in intact proviral load in 114 CD4+ T cells (median 103 vs 103 intact provirus per million CD4, p=0.55; Supplemental Figure 115 2B).

116

117 Additionally, we found that the frequencies of CD4+ T cells with any detectable proviral fragment 118 was directly proportional to the levels of IL1B (0.0025, Figure 1C), IL2 (p=0.0002, Figure 1D), 119 IL12p70 (p=0.0093), and IL13 (p=0.0067). After Bonferroni correction for the 8 analyzable cytokines, (cutoff p_{adi}=0.05/8=0.006), the association between plasma IL-1B and IL2 and CD4 120 121 containing HIV gag or pol remained statistically significant. The difference in IL1B and IL2 levels 122 between the TB and no-TB groups was not statistically significant (p=0.08 and p=0.1, 123 respectively), but by observation of the fit lines for the cytokine levels by proviral load, the levels 124 were overall higher for the TB group than for the non-TB group (Figure 1C and 1D).

125

126 In our pilot and confirmatory cohorts, we documented significantly higher levels of intact HIV 127 proviruses in circulating CD4+ T cells of PLHIV with histories of bacteriologically confirmed 128 pulmonary TB. Levels of HIV DNA correlated directly with levels of the pro-inflammatory cytokines 129 IL1B and IL2 with a trend to higher levels in people with a history of TB. Strengths of the study

130 include the use of IPDA to discriminate intact versus defective HIV proviruses, translational 131 approach using samples from people who have experienced the true natural history of HIV-TB 132 coinfection, and confirmatory cohort testing. Limitations include incomplete CD4+ T cell count 133 nadir data because of the changing landscape of CD4 testing in HIV care, inclusion of only 134 bacteriologically confirmed pulmonary TB, and HIV proviral load testing at only a single time point. 135 This is the first assessment of HIV provirus using IPDA in a clinical cohort from a resource limited 136 setting, and the finding of 8-fold larger reservoir in PLHIV with history of TB has significant 137 implications for our understanding of TB-HIV coinfection and HIV cure efforts in TB-endemic 138 settings.

139

PLHIV with TB exhibit systemic inflammation and immune activation. Local inflammation has the propensity to increase HIV replication and viral load at sites where HIV and replicating Mtb exist, even prior to the development of symptomatic TB (6). Mtb cell wall components are able to activate TLR signaling to induce HIV replication without live bacteria and may induce HIV transcription in neighboring cells that are uninfected with Mtb (6). These factors may contribute to the larger HIV reservoir in PLHIV with history of pulmonary TB, and should make TB a serious consideration for all reservoir-targeting HIV cure endeavors.

148 Supplemental Information

149 **1. Supplemental materials and methods**

Sex as a biological variable. This study included men and women. A post-hoc analysis with
 stratification by sex was performed which showed similar findings of statistically significantly
 higher percentage of CD4+ T cells containing intact provirus in people with history of pulmonary
 TB.

154

Study site. The prevalence of HIV in adults in Haiti was 1.8% in 2021. Haiti has the highest rate of TB in the Americas with 154 new cases of TB per 100,000 people in 2022, of whom 15% were HIV-positive (7). GHESKIO centers in Port au Prince, Haiti is a Haitian non-profit organization that is the largest provider of HIV and TB care in the Americas.

159

160 <u>Clinical cohorts</u>

161 For the pilot study, people with microbiologically confirmed pulmonary TB were enrolled from TB 162 ambulatory care centers at GHESKIO as part of a study on tuberculosis. People living with HIV 163 with or without history of TB were enrolled from the TB and HIV clinics at GHESKIO. Latent TB testing was using the Quantiferon-TB Gold In-Tube interferon-gamma release assay (IGRA) 164 165 (Qiagen, MD, USA). Blood for peripheral blood mononuclear cell (PBMC) isolation was collected 166 with heparin as an anticoagulant. The pilot nested case-control study included people with new 167 diagnosis of bacteriologically confirmed pulmonary TB, people with history of bacteriologically 168 confirmed pulmonary TB, and people with no history of TB who were either IGRA positive or IGRA 169 negative.

170

For the confirmatory study, volunteer participants were enrolled in a study of the human immune response to TB with an emphasis on recurrent TB at GHESKIO. Participants had HIV and were receiving suppressive ART with a history of zero, one, or two episodes of TB after HIV diagnosis.

They had one study visit with questionnaire, demographics, and phlebotomy. Latent TB testing was using the Quantiferon-TB Gold Plus In-Tube interferon-gamma release assay (IGRA) (Qiagen, MD, USA). Blood for peripheral blood mononuclear cell (PBMC) isolation was collected with EDTA as an anticoagulant.

178

For both studies, PBMC were isolated at GHESKIO using density gradient separation (Ficoll-Hypaque, GE Healthcare) with 5x10⁶ cell aliquots frozen and then shipped to New York where they were stored at -135C. PBMC specimens were identified with a unique patient identifier which did not correspond to their TB status. For analysis, participants were assigned to TB and no-TB groups after laboratory assessments were complete.

184

185 Intact proviral DNA assay (IPDA)

For each participant, one aliquot of 5x10⁶ cells was thawed and washed before CD4+ T cell 186 isolation by negative selection (EasySep[™] Human CD4+ T cell Enrichment Kit, Stem Cell 187 188 Technologies). DNA was then isolated using a column-based method (DNeasy Miniprep Kit, 189 Qiagen) and quantitated using Nanodrop (Thermo Fisher Scientific). Intact proviral DNA 190 amplification was determined using droplet digital PCR (ddPCR) on a QX200 instrument (Bio-191 Rad) (4). Amplification of the HIV gag (psi) and pol regions and human rpp30 were done 192 independently in parallel with quadruple technical replicates and for DNA shearing using rpp30. 193 PCR reactions with fewer than 10,000 droplets read were excluded from the calculation for that participant. Participants who did not have any detectable env or psi amplification using the primers 194 195 and conditions described in Bruner et al (4) and Gunst et al (8) were re-run with secondary env 196 primers and probes as described in Kinloch et al (5). Participants with no amplifiable HIV DNA 197 (gag fragment and psi fragment) with both primer sets were also excluded (n=1). From the ddPCR, we generated numbers of 3' defective (env), 5' defective (psi), and presumed intact 198 199 provirus containing both env and psi per million CD4+ T cells.

201 <u>HIV viral load</u>

Blood from participants in the pilot TBRU study were collected with heparin as the anticoagulant, so viral load results were not reliable. Instead, we tested plasma for HIV circulating p24 gag protein using an ELISA (RETRO-TEK[™] HIV-1 p24 Antigen ELISA, ZeptoMetrix, Buffalo, NY) with immune dissociation and reactive confirmation (HIV-1 p24 ICx/CRx kit, ZeptoMetrix). Participants who had detectable p24 or who did not have plasma available for p24 testing were excluded from final analysis of the pilot cohort.

208

209 Participants in the TB recurrence study were to have had undetectable viral loads prior to 210 enrollment in the study. However, because of the impact that active HIV replication could have on 211 the IPDA, we measured p24 in these participants as well using plasma collected with EDTA 212 anticoagulant. Plasma was centrifuged at 10.000 xg for 10 minutes to remove particulates. RNA 213 was extracted from plasma using a semi-automated method and HIV viral load quantitated using 214 a previously described integrase single copy assay (9, 10). Participants who had viral load > 1,000 215 copies/mL and detectable p24 after immune dissociation and neutralization were excluded. 216 Samples were analyzed on an ABI Viia7 Real-Time PCR System. Cycle threshold values were 217 compared with a validated HIV RNA standard run to determine concentration.

218

219 Cytokine levels

Plasma levels of granulocyte-macrophage colony-stimulating factor, interferon gamma, interleukin 1 beta (IL1B), interleukin 2 (IL2), interleukin 4 (IL4), interleukin 5 (IL5), interleukin 6 (IL6), interleukin 12p70 (IL12p70), interleukin 13 (IL13), interleukin 18 (IL18), and tumor necrosis factor (TNF) were measured using a bead-based multiplex assay (Th1/Th2 11-plex Human ProcartaPlex Panel, Invitrogen). Quantitation was performed using a Luminex MAGPIX system with xPONENT v4.3 software (Luminex, Austin, TX) according to the manufacturer's instructions with the following specifications. Plasma was spun at 10,000 xg for 10 minutes to remove particulates prior to aliquoting onto the plate. Incubation was overnight at room temperature. All samples were run in duplicate and the average reading used for quantitation with the standard curve. For samples that were less than the lower limit of detection, we imputed a value of half the difference between zero and the lowest concentration standard on the standard curve for each cytokine. Cytokines that were less than the level of detection for more than 50% of plasma samples did not continue to statistical analyses.

233

234 Data and Statistical analysis

235 Demographic and clinical characteristics were expressed as numbers and percentages with 236 interguartile range given for continuous variables. All statistical analysis was done in Stata 237 (version 18, College Station, TX, USA). Distributions of variables were tested using 238 Skewness/Kurtosis tests for normality. For normality test p< 0.05, Kruskal Wallis tests were used 239 to compare medians and for normality test p> 0.05, two-sided t-tests were used for comparison 240 of means. For proviral loads reported by IPDA as being less than the lower detection level, we 241 input a level of 1 copy per million CD4 for two reasons: 1) the fact that these participants have uncured HIV means that their level can't be zero and 2) we analyzed proviral loads using log₁₀ 242 243 because of the large numerical distribution of proviral loads and log₁₀0 is undefined whereas 244 $\log_{10}1$ is zero. When there were a large number of undetectable ($\log_{10}1=0$) proviral loads, we 245 utilized tobit regression for left censoring of proviral loads that were less than the lower limit of 246 detection with the IPDA (11). After completing the Luminex plasma cytokine assay, we excluded 247 cytokines for which more than half of participants had a level less than the lower limit of detection. 248 We applied Bonferroni correction for multiple analyses using the remaining number of cytokines 249 as the correction factor. We used Pearson's correlation coefficient (<pwcorr> in Stata) to compare 250 quantities of provirus and cytokines. For all analyses, the cutoff for significance was p≤0.05.

For a post-hoc analysis, we compared the rates of usage of alternative primers in the IPDA to determine if differences in proviral loads between TB and non-TB groups were related to use of different primer sets. The rates of primer usage by group are included in Supplemental Tables 1, 2, and 3. For the first cohort, where there was a statistically significant difference in use of alternate primers between the groups, we stratified by primer type and compared log intact proviral load between TB groups separately in those samples amplified by original IPDA primers (p=0.0012) and those samples amplified by alternate primers (p=0.016).

259

260 <u>Study approval</u>

This study was approved by institutional review boards at Weill Cornell Medicine and GHESKIO Centers. Study participants provided written informed consent. All participants were offered antiretroviral and anti-TB treatment and continuing care for HIV and TB per the Haitian national guidelines and the GHESKIO standard of care.

265

266 Data availability

The data used to generate the figures and supplemental figures are included in the Supporting Data Values document. Additional information is available from the authors upon reasonable request.

270

271 **2. Financial Contributions**

The authors recognize funding to KD (NIH K23-AI131913 and R01-AI176943, Doris Duke Charitable Foundation Clinical Scientist Development Award) and DWF (NIH U19-AI111143, P30-AI168433, and K24-AI098627). Additionally, this project utilized databases maintained in REDCap, supported by UL1-TR002385 from the National Center for Advancing Translational Sciences of the NIH. We acknowledge the patient care, clinical research, and laboratory teams at GHESKIO Centers in Port au Prince, Haiti.

279	3. Supplemental references				
280	7.	WHO. Tuberculosis profile: Haiti.			
281	8.	Gunst JD, Pahus MH, Rosas-Umbert M, Lu IN, Benfield T, Nielsen H, et al. Early			
282	interve	ntion with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with			
283	HIV-1:	a phase 1b/2a, randomized trial. Nat Med. 2022;28(11):2424-35.			
284	9.	Cillo AR, Vagratian D, Bedison MA, Anderson EM, Kearney MF, Fyne E, et al. Improv			
285	single-	copy assays for quantification of persistent HIV-1 viremia in patients on suppressive			
286	antiret	roviral therapy. J Clin Microbiol. 2014;52(11):3944-51.			
287	10.	McCann CD, van Dorp CH, Danesh A, Ward AR, Dilling TR, Mota TM, et al. A			
288	participant-derived xenograft model of HIV enables long-term evaluation of autologous				
289	immun	otherapies. J Exp Med. 2021;218(7).			
290	11.	Tobin J. Estimation of Relationships for Limited Dependent-Variables. Econometrica.			
291	1958;2	26(1):24-36.			
292					
293	4. Aut	hor Contributions			
294	MAJJ*	- clinical studies (TBRU – pilot cohort), acquire data			
295	YJ* - c	linical studies (TB recurrence – confirmatory cohort), acquire data			
296	DL – c	linical studies (TB recurrence – confirmatory cohort), acquire data			
297	AA – te	echnical expertise			
298	PJ - co	onduct experiments, write manuscript			
299	MHL –	analyze data			

- 300 MW – conduct experiments, acquire data
- 301 EB- conduct experiments, acquire data
- 302 YD- conduct experiments, acquire data
- UC conduct experiments, acquire data 303

et al. Improved

- 304 AD– conduct experiments, acquire data
- 305 WCA- conduct experiments, acquire data
- 306 DWF design research studies, data interpretation
- 307 JWP design research studies
- 308 RBJ– design research studies, analyze data, data interpretation
- 309 KMD design research studies, conduct experiments, acquire data, analyze data, data
- 310 interpretation, write manuscript

REFERENCES

312	Main References	

313 1. de Oliveira MF, Murrell B, Perez-Santiago J, Vargas M, Ellis RJ, Letendre S, et al.

314 Circulating HIV DNA Correlates With Neurocognitive Impairment in Older HIV-infected Adults on

315 Suppressive ART. Sci Rep. 2015;5:17094.

316 2. Olson A, Ragan EJ, Nakiyingi L, Lin N, Jacobson KR, Ellner JJ, et al. Brief Report:

317 Pulmonary Tuberculosis Is Associated With Persistent Systemic Inflammation and Decreased

318 HIV-1 Reservoir Markers in Coinfected Ugandans. J Acquir Immune Defic Syndr.

319 2018;79(3):407-11.

320 3. Xun J, Qi T, Zou L, Tang Q, Shen Y, Yang J, et al. Mycobacterium tuberculosis co-

infection is associated with increased surrogate marker of the HIV reservoir. AIDS Res Ther.2020;17(1):63.

4. Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, et al. A

324 quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature.

325 2019;566(7742):120-5.

5. Kinloch NN, Ren Y, Conce Alberto WD, Dong W, Khadka P, Huang SH, et al. HIV-1

327 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). Nat

328 Commun. 2021;12(1):165.

329 6. Waters R, Ndengane M, Abrahams M, Diedrich C, Wilkinson R, Coussens A. The Mtb-

330 HIV syndemic interaction: why treating M. tuberculosis infection may be crucial for HIV-1

331 eradication. Future Virology. 2020;15(2):101-25.

332 Supplemental References

333 7. WHO. Tuberculosis profile: Haiti.

8. Gunst JD, Pahus MH, Rosas-Umbert M, Lu IN, Benfield T, Nielsen H, et al. Early

intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with

336 HIV-1: a phase 1b/2a, randomized trial. Nat Med. 2022;28(11):2424-35.

- 337 9. Cillo AR, Vagratian D, Bedison MA, Anderson EM, Kearney MF, Fyne E, et al. Improved
- 338 single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive
- antiretroviral therapy. J Clin Microbiol. 2014;52(11):3944-51.
- 10. McCann CD, van Dorp CH, Danesh A, Ward AR, Dilling TR, Mota TM, et al. A
- 341 participant-derived xenograft model of HIV enables long-term evaluation of autologous
- immunotherapies. J Exp Med. 2021;218(7).
- Tobin J. Estimation of Relationships for Limited Dependent-Variables. Econometrica.
 1958;26(1):24-36.
- 345
- 346

347 Figure Legends:

Figure 1. There was approximately 8-fold higher circulating CD4 T cells with intact HIV provirus
in PLHIV with TB or TB history compared with no history of TB (p=0.0001, 1A). This was also
found in a confirmatory cohort (p=0.03, 1B). In the confirmatory cohort, plasma IL1B (1C) and
IL2 (1D) levels correlated with circulating CD4 T cells containing HIV gag and/or pol (p=0.0025
and p=0.0002, respectively).

353

Supplemental Figure 1. Subgroup analysis in the full pilot cohort of intact proviral load in
circulating CD4 T cells. There was no statistically significant difference between intact provirus
levels for people with active vs treated pulmonary TB disease (p=0.92, S1A) or by IGRA
positivity in people with no history of active pulmonary TB (p=0.96, S1B). Red pluses are the
medians.

360 <u>Supplemental Figure 2.</u> There was no statistically significant difference in intact provirus in 361 people without TB with different IGRA status at the time of study enrollment (S2A). There was 362 also no statistically significant difference in intact provirus in people with TB history with 363 recurrent vs only one episode of TB (S2B). Red pluses are the medians.

	TB group		No TB group	
	(n=50)		(n=50)	
	Untreated TB	History of TB or on treatment	IGRA-positive	IGRA-negative
	(n=25)	(n=25)	(n=25)	(n=25)
Sex (#female (%))	10 (40%)	14 (56%)	16 (64%)	17 (68%)
Age in years (mean +/- SD)	38.16 +/- 7.5	38.8 +/- 6.8	44 +/- 5.9	44 +/- 4.3
Time since HIV dx in years	0.02 (0.02-	3.1 (1.1-5.4)	12.8 (11.7-	11 (10.5-14.7)
(median (IQR))	0.03)		14.3)	
Time on ART in years (median	0	2.9 (0.9-4.5)	10 (8.7-10.7)	8.9 (8-10.2)
(IQR))				
Time between diagnosis and	.06 (0.02-	0.9 (0.457)	2.7 (2.3-4.1)	2.6 (1.3-4.7)
ART (median (IQR))	0.07)			
Alternate IPDA primers used	7 (28%)	9 (36%)	4 (16%)	3 (12%)
(number (%))				

365 Supplemental Table 1. Demographics of the pilot cohort

	TB group	No TB groups
	(n=18)	(n=13)
Sex (#female (%))	10 (55%)	7 (54%)
Age (mean +/- SD)	44 +/- 10.1	43.3 +/- 12.1
Time since HIV dx in years (median (IQR))	6.7 (5.4, 7.8)	6.4 (4.7, 7.9)
Time on ART in years (median (IQR))	6.2 (4.1, 7)	5 (4, 6.5)
Time between diagnosis and ART (median (IQR))	0.1 (0, 0.2)	0.8 (0, 1.6)
HIV viral load (median, (IQR))	0 (0-518)	0 (0-77)
Alternate IPDA primers used (number (%))	4 (22.2%)	3 (23%)

Supplemental Table 2. Demographics of the final analyzed group in the confirmatory cohort

370

Figure 1. There was approximately 8-fold higher circulating CD4 T cells with intact HIV provirus in PLHIV with TB or TB history compared with no history of TB (p=0.0001, 1A). This was also found in a confirmatory cohort (p=0.03, 1B). In the confirmatory cohort, plasma IL1B (1C) and IL2 (1D) levels correlated with circulating CD4 T cells containing HIV gag and/or pol (p=0.0025 and p=0.0002, respectively)



10

10.5

11

1C. Plasma IL1B correlates with CD4 containing HIV gag or pol 100000 Total cells with HIV DNA per million CD4 10000 ΤВ No TB 1000 TB p=0.026 No TB p=0.49 All p=0.0025 100 10 7 5 6 8 9 10 Plasma IL1B(pg/mL)

1D. Plasma IL2 correlates with CD4 containing HIV gag or pol

11.5

Plasma IL2 (pg/mL)

12

12.5

Supplemental Figure 1. Subgroup analysis in the full pilot cohort of intact proviral load in circulating CD4 T cells. There was no statistically significant difference between intact provirus levels for people with active vs treated pulmonary TB disease (p=0.92, S1A) or by IGRA positivity in people with no history of active pulmonary TB (p=0.96, S1B). Red pluses are the medians.





Supplemental Figure 2. There was no statistically significant difference in intact provirus in people without TB with different IGRA status at the time of study enrollment (S2A). There was also no statistically significant difference in intact provirus in people with TB history with recurrent vs only one episode of TB (S2B). Red crosses are the medians.



